Scinai Immunotherapeutics Ltd. (NASDAQ:SCNI – Get Free Report) shares fell 2% during mid-day trading on Tuesday . The stock traded as low as $0.49 and last traded at $0.50. 5,824 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 26,258 shares. The stock had previously closed at $0.51.
Scinai Immunotherapeutics Trading Down 2.0 %
The business has a fifty day simple moving average of $0.50. The company has a market capitalization of $935,000.00, a P/E ratio of -0.15 and a beta of 2.50.
Scinai Immunotherapeutics Company Profile
Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases, and other illnesses in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications.
Featured Articles
- Five stocks we like better than Scinai Immunotherapeutics
- The 3 Best Fintech Stocks to Buy Now
- 3 Stocks With Unusual Call Option Activity
- How Can Investors Benefit From After-Hours Trading
- Trump Media & Technology Group Soars on Market Debut
- Stock Market Upgrades: What Are They?
- 3 Stocks Insiders Are Buying That Analysts Love
Receive News & Ratings for Scinai Immunotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scinai Immunotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
